- Home
- ROIV vs RYAN Comparison
ROIV vs RYAN Comparison
Compare ROIV & RYAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- RYAN
- Stock Information
- Founded
- ROIV 2014
- RYAN 2010
- Country
- ROIV United Kingdom
- RYAN United States
- Employees
- ROIV N/A
- RYAN 4917
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- RYAN Specialty Insurers
- Sector
- ROIV Health Care
- RYAN Finance
- Exchange
- ROIV Nasdaq
- RYAN Nasdaq
- Market Cap
- ROIV 8.8B
- RYAN 8.0B
- IPO Year
- ROIV N/A
- RYAN 2021
- Fundamental
- Price
- ROIV $11.57
- RYAN $64.01
- Analyst Decision
- ROIV Strong Buy
- RYAN Buy
- Analyst Count
- ROIV 8
- RYAN 12
- Target Price
- ROIV $17.93
- RYAN $73.50
- AVG Volume (30 Days)
- ROIV 5.3M
- RYAN 979.2K
- Earning Date
- ROIV 02-11-2025
- RYAN 10-30-2024
- Dividend Yield
- ROIV N/A
- RYAN 0.69%
- EPS Growth
- ROIV N/A
- RYAN 53.91
- EPS
- ROIV 5.89
- RYAN 0.77
- Revenue
- ROIV $129,128,999.00
- RYAN $2,324,982,000.00
- Revenue This Year
- ROIV $15.98
- RYAN $26.17
- Revenue Next Year
- ROIV N/A
- RYAN $20.30
- P/E Ratio
- ROIV $2.06
- RYAN $82.66
- Revenue Growth
- ROIV 145.68
- RYAN 20.14
- 52 Week Low
- ROIV $9.69
- RYAN $41.61
- 52 Week High
- ROIV $13.06
- RYAN $75.97
- Technical
- Relative Strength Index (RSI)
- ROIV 41.56
- RYAN 29.07
- Support Level
- ROIV $11.72
- RYAN $63.10
- Resistance Level
- ROIV $12.22
- RYAN $67.85
- Average True Range (ATR)
- ROIV 0.30
- RYAN 1.62
- MACD
- ROIV -0.09
- RYAN -0.97
- Stochastic Oscillator
- ROIV 15.24
- RYAN 7.69
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.